Fawn Connor-Stroud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fawn Connor-Stroud has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer S. Wood
Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA
3 shared publications - Mirko Paiardini
Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University
3 shared publications - Sherrie M. Jean
Division of Animal Resources, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA
3 shared publications - Sudhir Pai Kasturi
Emory National Primate Research Center and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA
3 shared publications - Gregory K. Tharp
Emory National Primate Research Center, Atlanta, Georgia, USA
2 shared publications - Guido Silvestri
Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, USA
2 shared publications
Latest Publications
- 28 July 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (85) , eadg0033
Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques
Type I interferons (IFN-I) are critical mediators of innate control of viral infections but also drive the recruitment of inflammatory cells to sites of infection, a key feature of severe coronavirus disease 2019. Here, IFN-I signaling was modulated in rhesus macaques (RMs) before and during acute SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection using a mutated IFN-α2 (IFN-modulator; IFNmod), which has previously been shown to reduce the binding and signaling of endogenous IFN-I. IFNmod treatment in uninfected RMs was observed to induce a modest up-regulation of only antiviral IFN-stimulated genes (ISGs); however, in SARS-CoV-2–infected RMs, IFNmod reduced both antiviral and inflammatory ISGs. IFNmod treatment resulted in a potent reduction in SARS-CoV-2 viral loads both in vitro in Calu-3 cells and in vivo in bronchoalveolar lavage (BAL), upper airways, lung, and hilar lymph nodes of RMs. Furthermore, in SARS-CoV-2–infected RMs, IFNmod treatment potently reduced inflammatory cytokines, chemokines, and CD163 + MRC1 − inflammatory macrophages in BAL and expression of Siglec-1 on circulating monocytes. In the lung, IFNmod also reduced pathogenesis and attenuated pathways of inflammasome activation and stress response during acute SARS-CoV-2 infection. Using an intervention targeting both IFN-α and IFN-β pathways, this study shows that, whereas early IFN-I restrains SARS-CoV-2 replication, uncontrolled IFN-I signaling critically contributes to SARS-CoV-2 inflammation and pathogenesis in the moderate disease model of RMs.
- 28 July 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (85) , eadg0033
Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques
Type I interferons (IFN-I) are critical mediators of innate control of viral infections but also drive the recruitment of inflammatory cells to sites of infection, a key feature of severe coronavirus disease 2019. Here, IFN-I signaling was modulated in rhesus macaques (RMs) before and during acute SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection using a mutated IFN-α2 (IFN-modulator; IFNmod), which has previously been shown to reduce the binding and signaling of endogenous IFN-I. IFNmod treatment in uninfected RMs was observed to induce a modest up-regulation of only antiviral IFN-stimulated genes (ISGs); however, in SARS-CoV-2–infected RMs, IFNmod reduced both antiviral and inflammatory ISGs. IFNmod treatment resulted in a potent reduction in SARS-CoV-2 viral loads both in vitro in Calu-3 cells and in vivo in bronchoalveolar lavage (BAL), upper airways, lung, and hilar lymph nodes of RMs. Furthermore, in SARS-CoV-2–infected RMs, IFNmod treatment potently reduced inflammatory cytokines, chemokines, and CD163 + MRC1 − inflammatory macrophages in BAL and expression of Siglec-1 on circulating monocytes. In the lung, IFNmod also reduced pathogenesis and attenuated pathways of inflammasome activation and stress response during acute SARS-CoV-2 infection. Using an intervention targeting both IFN-α and IFN-β pathways, this study shows that, whereas early IFN-I restrains SARS-CoV-2 replication, uncontrolled IFN-I signaling critically contributes to SARS-CoV-2 inflammation and pathogenesis in the moderate disease model of RMs.
- Open Access
- 8 December 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (23)
Dynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART
Understanding viral rebound in pediatric HIV-1 infection may inform the development of alternatives to lifelong antiretroviral therapy (ART) to achieve viral remission. We thus investigated viral rebound after analytical treatment interruption (ATI) in 10 infant macaques orally infected with SHIV.C.CH505 and treated with long-term ART. Rebound viremia was detected within 7 to 35 days of ATI in 9 of 10 animals, with posttreatment control of viremia seen in 5 of 5 Mamu-A*01 + macaques. Single-genome sequencing revealed that initial rebound virus was similar to viral DNA present in CD4 + T cells from blood, rectum, and lymph nodes before ATI. We assessed the earliest sites of viral reactivation immediately following ATI using ImmunoPET imaging. The largest increase in signal that preceded detectable viral RNA in plasma was found in the gastrointestinal (GI) tract, a site with relatively high SHIV RNA/DNA ratios in CD4 + T cells before ATI. Thus, the GI tract may be an initial source of rebound virus, but as ATI progresses, viral reactivation in other tissues likely contributes to the composition of plasma virus. Our study provides potentially novel insight into the features of viral rebound in pediatric infection and highlights the application of a noninvasive technique to monitor areas of HIV-1 expression in children.
- 8 December 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (23)
Open AccessDynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART
Understanding viral rebound in pediatric HIV-1 infection may inform the development of alternatives to lifelong antiretroviral therapy (ART) to achieve viral remission. We thus investigated viral rebound after analytical treatment interruption (ATI) in 10 infant macaques orally infected with SHIV.C.CH505 and treated with long-term ART. Rebound viremia was detected within 7 to 35 days of ATI in 9 of 10 animals, with posttreatment control of viremia seen in 5 of 5 Mamu-A*01 + macaques. Single-genome sequencing revealed that initial rebound virus was similar to viral DNA present in CD4 + T cells from blood, rectum, and lymph nodes before ATI. We assessed the earliest sites of viral reactivation immediately following ATI using ImmunoPET imaging. The largest increase in signal that preceded detectable viral RNA in plasma was found in the gastrointestinal (GI) tract, a site with relatively high SHIV RNA/DNA ratios in CD4 + T cells before ATI. Thus, the GI tract may be an initial source of rebound virus, but as ATI progresses, viral reactivation in other tissues likely contributes to the composition of plasma virus. Our study provides potentially novel insight into the features of viral rebound in pediatric infection and highlights the application of a noninvasive technique to monitor areas of HIV-1 expression in children.
- Open Access
- 29 July 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 6 (61)
A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates
An adjuvanted monomeric RBD immunogen induces immunogenicity and protective immunity against SARS-CoV-2 in rhesus macaques.
- 29 July 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 6 (61)
Open AccessA yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates
An adjuvanted monomeric RBD immunogen induces immunogenicity and protective immunity against SARS-CoV-2 in rhesus macaques.
- Open Access
- 19 June 2019
- Published by Springer Nature in Lab Animal
- Vol. 48 (7) , 188
Should the IACUC oversee teaching protocols using farm animals?
- 19 June 2019
- Published by Springer Nature in Lab Animal
- Vol. 48 (7) , 188
Open AccessShould the IACUC oversee teaching protocols using farm animals?
- 1 January 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 25 (1) , 305-315
An evaluation of central penetration from a peripherally administered oxytocin receptor selective antagonist in nonhuman primates
- 1 January 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 25 (1) , 305-315
An evaluation of central penetration from a peripherally administered oxytocin receptor selective antagonist in nonhuman primates